[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587930":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":58,"collaborators":24,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":24,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Mỹ Đức Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Combination of LE and CC group","ACTIVE_COMPARATOR","5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) and 50 milligrams CC (Duinum 50 milligrams, Medochemie, Cyprus) per day, starting on the second to the fourth day of the cycle, for five consecutive days.",[13],"Procedure: IUI or intercourse",{"label":15,"type":10,"description":16,"interventionNames":17},"LE alone group","5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland), starting on the second to the fourth day of cycle, for five consecutive days.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","IUI or intercourse","5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) and 50 milligrams CC (Duinum 50 milligrams, Medochemie, Cyprus) or 5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) will be started on the second to the fourth day of the cycle, for five consecutive days. An ultrasound will be carried out three days after the last dose of medicine (day 8 of OI) to evaluate ovarian follicles' growth and the endometrium's thickness. If the follicular diameter reach ≥14 millimetres, check-up will be planned every two days until it reaches 18 millimetres. If there is the appearance of at least one follicle reaching 18 millimetres or more, a human chorionic gonadotropin (hCG) injection (IVF-C 5000 IU, LG Life Science, Korea) will be administered on the same day of the ultrasound in order to induce ovulation. IUI will be scheduled 36 - 38 hours after hCG injection or intercourse will be scheduled in the next day.",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Lan N Vuong, PhD,MD","University of Medicine and Pharmacy at Ho Chi Minh City","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Van TT Tran, MD","CONTACT","+84353345020","bsvan.ttt@myduchospital.vn",{"name":37,"role":33,"phone":24,"phoneExt":24,"email":38},"Vinh Q Dang, MSc,MD","vinh.dang@monash.edu",[40],{"facility":41,"status":42,"city":43,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"My Duc Hospital","RECRUITING","Ho Chi Minh City","70000","Vietnam","VN",{"type":48,"coordinates":49},"Point",[50,51],106.62965,10.82302,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":24,"email":57},"Tuong M Ho, MSc,MD","+84 90 3633377","tuongho.ivfmd@gmail.com",{"type":59,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100587930","le--cc-vs-le-for-ovulation-induction-100587930",false,"NCT06934785","LE + CC vs. LE for Ovulation Induction","The Combination of Letrozole (LE) and Clomiphene Citrate (CC) or LE Alone for Ovulation Induction in Women With WHO Group II\u002FIV Ovulatory Disorders: A Randomized Controlled Trial","COLA","Inclusion Criteria:\n\n* Women 18-40 years of age\n* Having WHO II\u002FIV ovulatory disorders (length of cycle \\\u003C 21 or \\> 35 days or having \\\u003C 8 cycles per year)\n* Progressive motility (PR) ≥ 32%, sperm concentration ≥ 5 million\u002Fml, total progressive motility sperm count \\> 5 million (World Health Organization, 2021)\n* Written informed consent.\n* Not participating in other studies.\n\nExclusion Criteria:\n\n* Untreated thyroid disease; Thyroid disease is suspected if patients have one of these (Bednarczuk et al., 2021); TSH ≥4 mIU\u002FL or TSH ≥2.5mIU\u002FL and TPOAb (+) or TSH \\\u003C0.1mIU\u002FL\n* Untreated hyper-prolactinemia; Hyperprolactinemia is suspected if patients have prolactinemia concentration \\>50 ng\u002FmL (The sample is collected after an overnight fast, at least 2 hours after waking up, ensuring that venipuncture does not cause excessive stress.)\n* Allergy or having contraindications to LE or CC;\n* Unilateral or Bilateral fallopian tube blockage (HSG, HyFoSy or surgery confirmation)\n* Untreated endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, or chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2; severe adenomyosis; congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate.","FEMALE","18 Years","40 Years",{"count":72,"type":73},600,"ESTIMATED","INTERVENTIONAL",[76],"NA","This randomized controlled trial (RCT) aims to evaluate whether, in infertile women with WHO II\u002FIV ovulatory disorders, a combination of letrozole (LE) and clomiphene citrate (CC) compared to LE alone, result in higher live birth rates.\n\nThe study is designed as an open-label, multicenter RCT across six fertility clinics in Vietnam. Participants will be randomized into two groups: (1) LE + CC , (2) LE alone. The primary outcome measure is the live birth rate after one treatment cycle. Based on prior data, the live birth rate for IUI in letrozole cycles is estimated at 12%. To detect a 10% increase in live birth rates with CC, 436 couples are needed (α = 0.05, power = 80%). Additionally, the live birth rate after IUI with LE-induced ovulation is approximately 18.7% (Diamond et al., 2015). To detect a 10% increase with CC, 560 couples are required (α = 0.05, power = 80%). Considering a 5% loss to follow-up and protocol deviations, the study plans to recruit 600 participants (150 per arm).",[79,80,81,82],"Letrozole","Clomiphene Citrate","Ovulation Disorder","Ovulation Induction","2025-09-04",{"date":85,"type":86},"2025-09-11","ACTUAL",{"date":88,"type":86},"2025-04-28",{"date":90,"type":73},"2027-06-30",{"name":5,"class":6},1]